Metropolitan Life Insurance Company (MetLife)’s Palvella Therapeutics PVLA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-224	Closed	-$61K	–	2567
2019 Q3	$61K	Buy	+224	New	+$86.7K	﹤0.01%	2478
2018 Q4	–	Sell	-196	Closed	-$87.7K	–	2576
2018 Q3	$87.7K	Hold	196	–	–	﹤0.01%	2505
2018 Q2	$79.4K	Buy	196 +18	+10%	+$8.57K	﹤0.01%	2405
2018 Q1	$97.3K	Buy	+178	New	+$110K	﹤0.01%	2304

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PVLA Position: Q4 2019 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Palvella Therapeutics (PVLA) in Q4 2019, closing a stake of 224 shares — an estimated $61K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PVLA in Q1 2018 and held it in 4 quarters. The position peaked at $97.3K in Q1 2018. 97 funds tracked by Wall St. Rank hold PVLA as of Q4 2019.

Metropolitan Life Insurance Company (MetLife) reported no remaining Palvella Therapeutics position as of Q4 2019 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 224 Palvella Therapeutics shares in Q4 2019, an estimated $61K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Palvella Therapeutics in Q1 2018 and held it in 4 quarters.
Metropolitan Life Insurance Company (MetLife)'s Palvella Therapeutics position peaked at $97.3K in Q1 2018.
97 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2019.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2019, filed 14 Feb 2020.